• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Amgen Inc.

    6/12/25 4:42:09 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMGN alert in real time by email
    11-K 1 a2024usplan11-k.htm 11-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington D.C. 20549
    FORM 11-K
    (Mark One)
     ýANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2024
    OR
     
     ¨TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    Commission file number 001-37702
    AMGEN RETIREMENT AND SAVINGS PLAN
    (Full title of the plan)
    AMGEN INC.
    (Name of issuer of the securities held)
     
    One Amgen Center Drive, 91320-1799
    Thousand Oaks, California (Zip Code)
    (Address of principal executive offices) 






    Amgen Retirement and Savings Plan
    Audited Financial Statements
    and Supplemental Schedule
    Year Ended December 31, 2024

    Contents
     
    Report of Independent Registered Public Accounting Firm
    1
    Audited Financial Statements:
    Statements of Net Assets Available for Benefits at December 31, 2024 and 2023
    2
    Statement of Changes in Net Assets Available for Benefits for the year ended December 31, 2024
    3
    Notes to Financial Statements
    4
    Supplemental Schedule:
    Schedule of Assets (Held at End of Year)
    11
    Index to Exhibit
    19
    Signatures
    20




    Report of Independent Registered Public Accounting Firm

    To the Plan Participants and the Plan Administrator of the Amgen Retirement and Savings Plan
    Opinion on the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of the Amgen Retirement and Savings Plan (the Plan) as of December 31, 2024 and 2023, and the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2024 and 2023, and the changes in its net assets available for benefits for the year ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.
    Basis for Opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.
    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
    Supplemental Schedule Required by ERISA
    The accompanying supplemental schedule of assets (held at end of year) as of December 31, 2024, (referred to as the “supplemental schedule”), has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The information in the supplemental schedule is the responsibility of the Plan’s management. Our audit procedures included determining whether the information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the information, we evaluated whether such information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.
    /s/ ERNST & YOUNG LLP

    We have served as the Plan’s auditor since at least 1989, but we are unable to determine the specific year.
    Los Angeles, California
    June 12, 2025

    1



    Amgen Retirement and Savings Plan
    Statements of Net Assets Available for Benefits

     December 31,
     20242023
    Assets
    Investments at fair value$7,032,543,261 $6,270,169,496 
    Investments in fully benefit-responsive investment contracts at contract value688,059,315 638,250,657 
    Notes receivable from participants35,591,211 31,248,315 
    Other – principally due from broker3,433,090 4,776,528 
    Total assets7,759,626,877 6,944,444,996 
    Liabilities
    Other – principally due to broker4,178,843 5,497,298 
    Total liabilities4,178,843 5,497,298 
    Net assets available for benefits$7,755,448,034 $6,938,947,698 
    See accompanying notes.

    2



    Amgen Retirement and Savings Plan
    Statement of Changes in Net Assets Available for Benefits

     Year Ended December 31,
     2024
    Additions to (deductions from) net assets:
    Employer contributions$268,014,992 
    Participant contributions237,183,261 
    Rollover contributions116,347,764 
    Interest and dividend income49,639,021 
    Net realized/unrealized gains688,876,587 
    Interest income on notes receivable from participants2,300,919 
    Benefits paid(536,100,983)
    Investment and administrative fees(9,761,225)
    Net increase816,500,336 
    Net assets available for benefits at beginning of year6,938,947,698 
    Net assets available for benefits at end of year$7,755,448,034 
    See accompanying notes.
    3



    Amgen Retirement and Savings Plan
    Notes to Financial Statements
    December 31, 2024
    1. Description of the Plan
    The following description of the Amgen Retirement and Savings Plan (the Plan) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.
    General
    The Plan was established effective April 1, 1985, and was amended and restated effective January 1, 2017. The Plan was subsequently amended, with the most recent amendment effective on or prior to December 31, 2024 adopted on December 18, 2023. The Plan was further amended on March 5, 2025, effective January 1, 2025. The Plan is a defined contribution plan covering substantially all domestic employees of Amgen Inc. (the Company or Amgen) and participating subsidiaries. The Plan is intended to qualify under sections 401(a) and 401(k) of the Internal Revenue Code of 1986 (the Code) (see Note 4, Income Tax Status) and section 407(d)(3)(A) of the Employee Retirement Income Security Act of 1974 (ERISA).
    Contributions
    Subject to certain limitations (as defined in the Plan), participants may elect to contribute up to 30% of their eligible compensation in pre-tax contributions, Roth contributions (in accordance with the Code), after-tax contributions or a combination of these types of contributions (together, Individual Contributions). A participant’s combined pre-tax contributions and Roth contributions (exclusive of catch-up contributions discussed below) are subject to Internal Revenue Service (IRS) and Plan limits and could not exceed a maximum of $23,000 in 2024. Participant after-tax contributions are subject to IRS and Plan limitations and could not exceed a maximum of $11,500 in 2024. Unless an employee has voluntarily enrolled in the Plan or has declined to participate in the Plan within the first 30 days of employment, all newly eligible participants are automatically enrolled in the Plan, and contributions equal to 5% of their eligible compensation are withheld and contributed to the Plan as pre-tax contributions; such contributions are automatically increased by 1% per year until their contributions reach 10% of their eligible compensation. Participants may elect to adjust, cease or resume their Individual Contributions at any time.
    Participants who are at least age 50 by the close of the Plan year may also elect to make certain additional Individual Contributions, referred to as catch-up contributions, that are subject to IRS and Plan limitations and could not exceed $7,500 in 2024. Catch-up contributions may be made as pre-tax contributions, Roth contributions or a combination of these types of contributions. Participants may also contribute pre-tax, Roth and after-tax amounts representing distributions from certain retirement plans qualified in the United States or certain individual retirement accounts (IRAs), referred to as rollover contributions (as defined in the Plan).
    Each pay period, the Company makes a non-elective contribution for all eligible participants, whether or not they have elected to make Individual Contributions to the Plan, equal to 5% of each participant’s eligible compensation (Core Contributions) up to a maximum of $17,250 in 2024. In addition, the Company makes a contribution equal to amounts contributed by the participant as pre-tax contributions or Roth contributions, including such contributions designated as catch-up contributions, of up to 5% of eligible compensation (Matching Contributions) up to a maximum of $17,250 in 2024.
    Also, the Company can, at its discretion, make a special contribution (Special Contribution) on behalf of a participant who is in his or her initial year of employment with the Company and who could not make the maximum participant contribution permitted under the Plan because in the same Plan year he or she previously made pre-tax salary deferrals under a prior unrelated employer’s qualified plan.
    Participants select the investments in which their Individual Contributions, including their Core Contributions, Matching Contributions and Special Contributions, if any, (collectively, Company Contributions) are to be invested, electing among various alternatives, including Amgen common stock (Amgen stock). Participants may direct a maximum of 20% of contributions to be invested in Amgen stock. In addition, participants may transfer amounts among the investment options at any time, subject to certain limitations. Notwithstanding the foregoing, if 20% or more of the value of a participant’s Plan account is invested in Amgen stock, the Plan document provides that no transfers from other investment options can be made to invest in Amgen stock.
    The accounts of participants who have not made an investment election are allocated to investments under a qualified default investment alternative, which is intended to be compliant with ERISA regulations. At any time, participants may elect to alter the investments in their accounts made under a qualified default investment alternative.
    4



    Amgen Retirement and Savings Plan
    Notes to Financial Statements (continued)
    Vesting
    Participants are immediately vested with respect to their Individual Contributions, Matching Contributions and Special Contributions, if any, and earnings and losses (hereafter referred to as earnings) thereon. Participants hired prior to January 1, 2020, are also immediately vested with respect to their Core Contributions and earnings thereon. Participants hired on or after January 1, 2020, vest in full with respect to their Core Contributions and earnings thereon after three years of service, as defined by the terms of the Plan, or upon reaching age 65 while employed by Amgen, if earlier. If a participant ceases to be an employee before fully vesting in their account, the non-vested Core Contributions and earnings thereon of the participant’s account is treated as a forfeiture, as defined by the terms of the Plan, on the earlier of (a) the date the participant incurs a five-year break in service, as defined by the terms of the Plan or, (b) the date the participant receives a distribution of the entire vested portion of their account.
    Participant Accounts
    Each participant’s account is credited with: (a) the participant’s Individual Contributions; (b) an allocation of Company Contributions; and (c) earnings. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s account.
    Plan Investments
    Plan participants can invest in seven different asset classes as well as Amgen stock or can actively manage their account under a self-directed brokerage arrangement in which a wider array of investment options are available. The value of an investment in an asset class is determined by its underlying investment vehicles, which may include one or more of the following: mutual funds, collective trust funds and portfolios which are separately managed exclusively for the benefit of Plan participants and their beneficiaries (separately managed portfolios). The separately managed portfolios invest in various types of assets, including publicly traded common and preferred stocks, collective trust funds and investment contracts. The asset classes are designed to provide participants with choices among a variety of investment objectives.
    Payments of Benefits
    Subject to Plan limitations, upon termination of employment, including termination due to disability (as defined in the Plan) or retirement, participants may elect to receive a full or partial distribution of their account balance in: (a) a single payment in cash; (b) a single distribution in full shares of Amgen stock (with any fractional shares paid in cash); (c) a single distribution paid in a combination of cash and full shares of Amgen stock; (d) cash installments over 10 years; or (e) a rollover distribution to an eligible retirement plan.
    Participants may also elect to maintain their account balance in the Plan subsequent to termination of employment, provided that their account balance is greater than $1,000.
    If a participant dies before receiving the value of his or her account balance, the participant’s beneficiary may elect to receive the distribution of remaining funds from among the alternatives described above, subject to certain Plan limitations.
    No withdrawals may be made from the Plan while a participant continues to be employed by the Company except in certain circumstances including, but not limited to, financial hardship, disability and attainment of age 59 1/2.
    Amgen Stock Dividends
    Participants that invest in Amgen stock may elect to receive distributions of cash with respect to dividends the Company pays on Amgen stock or reinvest such dividends to acquire additional shares of Amgen stock.
    Notes Receivable from Participants
    Subject to certain restrictions, a participant can have up to two loans outstanding at any one time from his or her Plan account with a combined maximum loan amount that may not exceed the lesser of: (a) 50% of the participant’s account balance (exclusive of amounts related to Roth contributions and earnings thereon) or (b) $50,000 less certain adjustments, as applicable (as defined in the Plan). A participant’s loan is secured by his or her Plan account balance. Loans bear interest at fixed rates which, until changed by the Company, are based on the prime rate plus one percentage point as published in The Wall Street Journal, determined as of the last day of the calendar quarter preceding origination or such other rate as may be required by law.
    5



    Amgen Retirement and Savings Plan
    Notes to Financial Statements (continued)
    Loans are generally payable in installments over periods of up to five years, unless the loan is used to acquire a principal residence for which the term of the loan may be up to 20 years. Principal and interest payments are allocated to the participant’s account.
    Plan Termination
    Although it has not expressed any intent to do so, the Company has the right under the Plan to terminate the Plan subject to the provisions of ERISA. Upon termination, participants would become fully vested in Core Contributions and receive distributions of their account balances.
    Trustees and Custodians
    Bank of America, N.A. is the Plan’s trustee and custodian with respect to the self-directed brokerage arrangement and the Amgen common stock fund. The Northern Trust Company, NA (Northern) is the Plan’s trustee and custodian with respect to the asset classes.
    2. Summary of Significant Accounting Policies
    Basis of Accounting
    The accompanying financial statements are prepared on the accrual basis of accounting. Benefits to participants are recorded when paid.
    Fair Value Measurement
    The investments of the Plan are reported at fair value, except for fully benefit-responsive investment contracts, discussed below. Fair value is generally defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date (see Note 3, Fair Value Measurements).
    Investment Income and Losses
    Dividend income is recognized on the ex-dividend date, and interest income is recorded on an accrual basis. Unrealized gains and losses on investments are measured by the change in the difference between the fair value and cost of the securities held at the beginning of the year (or date purchased if acquired during the Plan year) and the end of the year. Realized gains and losses from security transactions are recorded based on the weighted-average cost of securities sold.
    Fully Benefit-Responsive Investment Contracts
    As of December 31, 2024 and 2023, the Plan had fully benefit-responsive investment contracts, including synthetic investment contracts. The synthetic investment contracts are composed of wrapper contracts issued by insurance companies backed by the Plan’s ownership in collective trust funds that invest in fixed income securities. Contract value is the relevant measurement attribute for synthetic investment contracts because this is the amount participants would receive if they were to initiate qualified transactions related to these investments. The issuers of the Plan’s synthetic investment contracts credit the Plan with stated rates of interest, and the issuers guarantee that all qualified participant withdrawals related to the contracts will be at contract value, except as discussed below. The crediting rates provide for realized and unrealized gains and losses on the underlying assets to be amortized over the expected duration of the underlying investments through adjustments to the future interest crediting rates rather than being reflected immediately in the net assets of the Plan.
    The contract values of the Plan’s synthetic investment contracts were as follows:
    December 31,
    20242023
    Synthetic investment contracts$688,059,315 $638,250,657 
    Total fully benefit-responsive investment contracts$688,059,315 $638,250,657 
    The synthetic investment contracts provide for withdrawals at other than contract value associated with certain events which are not in the ordinary course of Plan operations. These withdrawals are made at contract value, modified by a market value adjustment as defined in the contract. Circumstances which may trigger a market value adjustment are generally defined as any
    6



    Amgen Retirement and Savings Plan
    Notes to Financial Statements (continued)
    event that, in the reasonable determination of the issuer, has or will have a material adverse effect on the issuer’s interest under the contract. Such events may include, but are not limited to: (a) material amendments to the Plan’s structure or administration; (b) changes in or the creation of competing investment options; (c) complete or partial termination of the Plan; (d) removal of a specifically identifiable group of employees from coverage under the Plan; (e) a change in law, regulation, ruling, administrative position, or accounting standard applicable to the Plan; or (f) communication to Plan participants designed to influence a participant not to invest in the asset class that contains these contracts. The Company does not believe that the occurrence of any such event, which would limit the Plan’s ability to transact at contract value with participants, is probable.
    These synthetic investment contracts are evergreen contracts with no maturity dates, but do contain termination provisions. The issuer is obligated to pay the excess contract value when the fair value of the underlying investments equals zero. In addition, if the Plan defaults in its obligations under the synthetic investment contract and such default is not corrected within the time permitted by the contract, then the contract may be terminated by the issuer and the Plan will receive the fair value of the underlying investments as of the date of termination.
    Notes Receivable from Participants
    Notes receivable from participants are carried at their unpaid balance plus accrued but unpaid interest, as applicable.
    Due from/to Brokers
    Purchases and sales of investments are recorded on a trade-date basis. Amounts due from and due to brokers arise from unsettled sale and purchase transactions, respectively.
    Use of Estimates
    The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements, accompanying notes and supplemental schedule. Actual results could differ from those estimates.
    Risks and Uncertainties
    The Plan provides for investment options representing varied combinations of equities (including Amgen stock), fixed income, and other investments. Investments, in general, particularly in securities, are exposed to various risks, such as interest rate, inflation, market and credit risks, among others. Market risk includes global events which could impact the value of investments, including securities, such as a pandemic or international conflict. Due to the level of risk associated with certain investments, including securities, it is at least reasonably possible that changes in the values of the Plan’s investments, including securities, will occur in the near term and that such changes could materially affect participant account balances and the amounts reported in the Plan’s financial statements.
    3. Fair Value Measurements
    The Plan uses various valuation approaches in determining the fair value of investments within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the investment based on market data obtained from independent sources. Unobservable inputs are inputs that reflect assumptions about the inputs that market participants would use in pricing the investment and are developed based on the best information available in the circumstances.
    7



    Amgen Retirement and Savings Plan
    Notes to Financial Statements (continued)
    The fair value hierarchy is divided into three levels based on the source of inputs as follows:
    Level 1 – Valuations based on unadjusted quoted prices in active markets for identical investments that the Plan has the ability to access
    Level 2 – Valuations for which all significant inputs are observable, either directly or indirectly, other than Level 1 inputs
    Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement
    The availability of observable inputs can vary among the various types of investments. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
    The following fair value hierarchy tables present information about each major class/category of the Plan’s investments measured at fair value:
     
    Fair value measurements at December 31, 2024, using
     Quoted prices in active markets for identical assets
    (Level 1)
    Significant
    other observable
    inputs
    (Level 2)
    Significant
    unobservable
    inputs
    (Level 3)
    Total
    Amgen stock$344,055,715 $— $— $344,055,715 
    Cash and cash equivalents3,466,558 — — 3,466,558 
    Collective trust funds— 5,003,198,779 — 5,003,198,779 
    Common and preferred stocks533,256,711 — — 533,256,711 
    Debt securities— 2,979 — 2,979 
    Mutual funds148,845,846 — — 148,845,846 
    Self-directed brokerage accounts996,397,298 3,319,375 — 999,716,673 
    Total investments at fair value$2,026,022,128 $5,006,521,133 $— $7,032,543,261 
     
    Fair value measurements at December 31, 2023, using
     Quoted prices in active markets for identical assets
    (Level 1)
    Significant
    other observable
    inputs
    (Level 2)
    Significant
    unobservable
    inputs
    (Level 3)
    Total
    Amgen stock$397,307,694 $— $— $397,307,694 
    Cash and cash equivalents5,271,619 — — 5,271,619 
    Collective trust funds— 4,193,149,196 — 4,193,149,196 
    Common and preferred stocks763,525,683 — — 763,525,683 
    Debt securities— 3,008 — 3,008 
    Mutual funds105,092,597 — — 105,092,597 
    Self-directed brokerage accounts801,100,962 4,718,737 — 805,819,699 
    Total investments at fair value$2,072,298,555 $4,197,870,941 $— $6,270,169,496 
    The fair values of substantially all common stocks (including Amgen stock), preferred stocks, publicly traded mutual funds and underlying investments of self-directed brokerage accounts are valued using quoted market prices in active markets with no valuation adjustment.
    8



    Amgen Retirement and Savings Plan
    Notes to Financial Statements (continued)
    Collective trust funds represent interests in pooled investment vehicles designed typically for collective investment of employee benefit trusts. The fair values of these investments are determined by reference to the net asset value per unit provided by the fund managers as the basis for current transactions.
    4. Income Tax Status
    The Plan received a determination letter from the IRS dated February 22, 2018, stating that, conditioned on the adoption of proposed Plan amendments submitted to the IRS on February 15, 2018, the Plan is qualified, in form, under Section 401(a) of the Code and, therefore, the related trust is exempt from taxation. There have been seven subsequent amendments to the Plan, including amendments to satisfy the conditions in the determination letter. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualification. The Company believes the Plan is currently being operated in compliance with the applicable requirements of the Code and, therefore, believes that the Plan is qualified and the related trust is tax exempt. The Company has indicated that it currently intends to continue to take the necessary steps, if any, to maintain the Plan’s compliance with the applicable requirements of the Code.
    5. Party-in-Interest Transactions
    Parties-in-interest are certain entities defined under Department of Labor regulations, including Amgen, and other parties that provide services to the Plan, such as the trustees, custodians and investment managers. The Plan pays the trustees certain administrative and investment management fees, and the Company pays certain administrative fees on behalf of the Plan. The Plan invests in collective trust funds managed by Northern, certain of the Plan’s investment managers and other third parties and may invest in securities of entities that are parties-in-interest. The Plan also invests in shares of common stock of Amgen and receives dividends on those shares. Notes receivable from participants are also considered party-in-interest transactions. In addition, an investment manager enters into synthetic investment contracts with certain insurance companies on behalf of the Plan.

    9



    Amgen Retirement and Savings Plan
    Notes to Financial Statements (continued)
    6. Reconciliation of Financial Statements to the Form 5500
    The reconciliation of net assets available for benefits per the financial statements to the Form 5500 consisted of the following:
     December 31,
     20242023
    Net assets available for benefits per the financial statements$7,755,448,034 $6,938,947,698 
    Adjustment to fair value for fully benefit-responsive investment contracts
    (37,044,409)(42,589,104)
    Amounts allocated to withdrawing participants(2,576,951)(2,426,100)
    Deemed loans(405,772)(433,392)
    Net assets per the Form 5500$7,715,420,902 $6,893,499,102 
    The following is a reconciliation of the net investment gain per the financial statements to the Form 5500: 
     Year Ended
    December 31,
    2024
    Interest and dividend income$49,639,021 
    Net realized/unrealized gains688,876,587 
    Net investment gain per the financial statements738,515,608 
    Adjustment from fair value to contract value for fully benefit-responsive investment contracts:
    Prior-year adjustment42,589,104 
    Current-year adjustment(37,044,409)
    Total net investment gain per the Form 5500$744,060,303 
    The following is a reconciliation of expenses per the financial statements to the Form 5500:
     Year Ended
    December 31,
    2024
    Benefits paid$(536,100,983)
    Investment and administrative fees(9,761,225)
    Total expenses per the financial statements(545,862,208)
    Amounts allocated to withdrawing participants at December 31, 2023
    2,426,100 
    Amounts allocated to withdrawing participants at December 31, 2024
    (2,576,951)
    Deemed loans at December 31, 2023
    433,392 
    Deemed loans at December 31, 2024
    (405,772)
    Total expenses per the Form 5500$(545,985,439)
    10


    Supplemental Schedule
    Amgen Retirement and Savings Plan
    EIN: 95-3540776 Plan: #001
    As of December 31, 2024
    Schedule H, line 4i – Schedule of Assets (Held at End of Year)
    Identity of IssueDescription of InvestmentCurrent Value
    Amgen stock*Employer Securities 1,320,042 shares$344,055,715 
    $344,055,715 
    Capital Preservation Asset Class:
    Galliard Intermediate Core Fund L*Collective Trust Fund 26,889,543 units388,268,871 
    Galliard Short Core Fund F*Collective Trust Fund 15,803,322 units262,746,035 
    Short-Term Investment Fund II*Collective Trust Fund 36,482,326 units36,482,326 
    NT Collective Short Term Investment Fund*Collective Trust Fund 54,278,427 units54,278,427 
    Wrapper Contracts— 
    Total Capital Preservation Asset Class741,775,659 
    Fixed Income Active Asset Class:
    MetLife Core Plus Collective Fund*Collective Trust Fund 8,096,601 units81,613,735 
    Wellington Core Bond Plus Portfolio Collective Investment Trust II*Collective Trust Fund 7,304,193 units81,149,579 
    NT Collective Aggregate Bond Index Fund / Non Lending*Collective Trust Fund 203,905 units30,628,555 
    Schroder Global Strategic Bond Trust Class W*Collective Trust Fund 2,345,420 units25,823,079 
    Banc America Alternative Loan Trust Series 2004-6 Class 4A 15.0% Due 10-25-2048*Corporate Bond 2,275 units1,887 
    GMAC Mortgage Loan Trust 2003/J10 4.75% Due 01/25/2019Corporate Bond 1,131 units1,092 
    NT Collective Short Term Investment Fund*Collective Trust Fund 340 units340 
    Total Fixed Income Active Asset Class219,218,267 
    Fixed Income Index Asset Class:
    NT Collective Aggregate Bond Index Fund / Non Lending*Collective Trust Fund 8,014,538 units1,203,863,804 
    Total Fixed Income Index Asset Class1,203,863,804 
    U.S. Equity Active Asset Class:
    NT Collective Russell 1000 Value Index Fund / Non Lending*Collective Trust Fund 178,521 units113,885,436 
    NT Collective Russell 3000 Index Fund / Non Lending*Collective Trust Fund 227,333 units21,106,461 
    Amazon Inc.Common and Preferred Stock 76,247 shares16,727,829 
    Nvidia CorporationCommon and Preferred Stock 111,652 shares14,993,747 
    Microsoft CorporationCommon and Preferred Stock 35,065 shares14,779,898 
    NT Collective Short Term Investment Fund*Collective Trust Fund 10,902,997 units10,902,997 
    Facebook Inc. Class ACommon and Preferred Stock 17,128 shares10,028,615 
    Apple Inc.Common and Preferred Stock 33,873 shares8,482,477 
    Visa Inc. Class ACommon and Preferred Stock 25,247 shares7,979,062 
    ServiceNow, Inc.Common and Preferred Stock 7,498 shares7,948,780 
    SS&C Technologies Holdings Inc.Common and Preferred Stock 81,488 shares6,175,161 
    Netflix, Inc.Common and Preferred Stock 5,895 shares5,254,331 
    Entegris Inc.Common and Preferred Stock 50,467 shares4,999,261 
    11



    Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)
    Identity of IssueDescription of InvestmentCurrent Value
    Atlassian Corporation Class ACommon and Preferred Stock 19,686 shares4,791,179 
    CVS Health CorporationCommon and Preferred Stock 105,737 shares4,746,534 
    UnitedHealth Group Inc.Common and Preferred Stock 9,326 shares4,717,650 
    Baxter International Inc.Common and Preferred Stock 160,897 shares4,691,757 
    Shopify Inc. Class ACommon and Preferred Stock 43,408 shares4,615,573 
    Intuit Inc.Common and Preferred Stock 7,241 shares4,550,969 
    S&P Global Inc.Common and Preferred Stock 8,979 shares4,471,811 
    Citigroup Inc.Common and Preferred Stock 61,883 shares4,355,944 
    Aon PLCCommon and Preferred Stock 11,976 shares4,301,300 
    Waste Management, Inc.Common and Preferred Stock 20,616 shares4,160,103 
    Gartner Inc.Common and Preferred Stock 8,524 shares4,129,622 
    Thermo Fisher Scientific Inc.Common and Preferred Stock 7,776 shares4,045,308 
    Yum! Brands, Inc.Common and Preferred Stock 29,586 shares3,969,258 
    Canadian Pacific Kansas City LimitedCommon and Preferred Stock 54,562 shares3,948,652 
    Halozyme Therapeutics Inc.Common and Preferred Stock 82,078 shares3,924,149 
    STERIS plcCommon and Preferred Stock 19,032 shares3,912,218 
    Clean Harbors Inc.Common and Preferred Stock 16,934 shares3,897,191 
    Danaher CorporationCommon and Preferred Stock 16,967 shares3,894,775 
    Novo Nordisk A/SCommon and Preferred Stock 44,759 shares3,850,169 
    Wells Fargo & Company*Common and Preferred Stock 54,547 shares3,831,381 
    Capital One Financial CorporationCommon and Preferred Stock 21,446 shares3,824,251 
    Dow Inc.Common and Preferred Stock 93,143 shares3,737,829 
    Datadog, Inc.Common and Preferred Stock 25,946 shares3,707,424 
    Fresenius Medical CareCommon and Preferred Stock 163,629 shares3,704,561 
    MSCI Inc.Common and Preferred Stock 6,074 shares3,644,461 
    Synopsys Inc.Common and Preferred Stock 7,292 shares3,539,245 
    Amphenol Corporation Class ACommon and Preferred Stock 50,848 shares3,531,394 
    Humana Inc.Common and Preferred Stock 13,894 shares3,525,047 
    Waste Connections Inc.Common and Preferred Stock 20,230 shares3,471,061 
    Euronet Worldwide Inc.Common and Preferred Stock 33,372 shares3,431,976 
    Dollar General CorporationCommon and Preferred Stock 45,041 shares3,415,009 
    Global Payments Inc.Common and Preferred Stock 30,288 shares3,394,073 
    Ecolab Inc.Common and Preferred Stock 14,359 shares3,364,601 
    RB Global Inc.Common and Preferred Stock 37,268 shares3,361,946 
    Workday, Inc.Common and Preferred Stock 12,972 shares3,347,165 
    Magna International Inc.Common and Preferred Stock 79,821 shares3,335,720 
    DexCom, Inc.Common and Preferred Stock 42,688 shares3,319,846 
    Merit Medical Systems Inc.Common and Preferred Stock 34,289 shares3,316,432 
    Spotify Technology S.A.Common and Preferred Stock 7,394 shares3,307,928 
    Alphabet Inc.Common and Preferred Stock 17,078 shares3,252,334 
    MetLife Inc.*Common and Preferred Stock 39,316 shares3,219,194 
    Sea LimitedCommon and Preferred Stock 29,479 shares3,127,722 
    Churchill Downs Inc.Common and Preferred Stock 23,263 shares3,106,541 
    Equitable Holdings Inc.Common and Preferred Stock 65,021 shares3,067,041 
    Lear CorporationCommon and Preferred Stock 32,352 shares3,063,734 
    Charter Communications Inc.Common and Preferred Stock 8,868 shares3,039,684 
    Samsara Inc. Class ACommon and Preferred Stock 69,516 shares3,037,154 
    Cognizant Technology Solutions Corporation Class ACommon and Preferred Stock 39,418 shares3,031,244 
    Block, Inc.Common and Preferred Stock 34,972 shares2,972,270 
    12



    Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)
    Identity of IssueDescription of InvestmentCurrent Value
    Autodesk, Inc.Common and Preferred Stock 9,975 shares2,948,311 
    Ametek Inc.Common and Preferred Stock 16,255 shares2,930,126 
    CarGurus Inc. Class ACommon and Preferred Stock 78,733 shares2,876,904 
    Trimble Inc.Common and Preferred Stock 40,642 shares2,871,764 
    Bank of America Corporation*Common and Preferred Stock 65,005 shares2,856,970 
    Cloudflare, Inc.Common and Preferred Stock 26,514 shares2,855,028 
    American Express CompanyCommon and Preferred Stock 9,522 shares2,826,034 
    BWX Technologies Inc.Common and Preferred Stock 24,242 shares2,700,316 
    Intercontinental Exchange, Inc.Common and Preferred Stock 18,047 shares2,689,183 
    Bio-Techne CorporationCommon and Preferred Stock 37,307 shares2,687,223 
    HealthEquity Inc.Common and Preferred Stock 27,378 shares2,626,919 
    J2 Global Inc.Common and Preferred Stock 47,244 shares2,567,239 
    Delta Air Lines, Inc.Common and Preferred Stock 41,633 shares2,518,797 
    Brown & Brown Inc.Common and Preferred Stock 24,520 shares2,501,530 
    Amdocs LimitedCommon and Preferred Stock 29,190 shares2,485,237 
    Alight Inc. Class ACommon and Preferred Stock 358,557 shares2,481,214 
    Pfizer Inc.Common and Preferred Stock 93,060 shares2,468,882 
    Bristol Myers SquibbCommon and Preferred Stock 43,459 shares2,458,041 
    ASML Holding N.V.Common and Preferred Stock 3,545 shares2,456,969 
    Skyworks Solutions IncCommon and Preferred Stock 27,136 shares2,406,420 
    Shell plcCommon and Preferred Stock 38,214 shares2,394,107 
    Voya Financial Inc.Common and Preferred Stock 34,500 shares2,374,635 
    Nu Holdings LimitedCommon and Preferred Stock 229,156 shares2,374,056 
    Ingredion Inc.Common and Preferred Stock 17,102 shares2,352,551 
    Okta Inc.Common and Preferred Stock 29,814 shares2,349,343 
    DoorDash, Inc. Class ACommon and Preferred Stock 13,674 shares2,293,814 
    Tyson Foods Inc.Common and Preferred Stock 39,902 shares2,291,971 
    Medtronic PLCCommon and Preferred Stock 27,901 shares2,228,732 
    LKQ CorporationCommon and Preferred Stock 60,322 shares2,216,834 
    Huntington Bancshares Inc.Common and Preferred Stock 135,001 shares2,196,466 
    Salesforce.com Inc.Common and Preferred Stock 6,545 shares2,188,190 
    AppLovin Corporation Class ACommon and Preferred Stock 6,657 shares2,155,736 
    IDEX CorporationCommon and Preferred Stock 10,262 shares2,147,734 
    Doximity Inc.Common and Preferred Stock 39,578 shares2,113,069 
    Starbucks CorporationCommon and Preferred Stock 23,069 shares2,105,046 
    Charles River Laboratories International Inc.Common and Preferred Stock 11,403 shares2,104,994 
    PVH CorporationCommon and Preferred Stock 19,544 shares2,066,778 
    Newell Brands Inc.Common and Preferred Stock 203,960 shares2,031,442 
    Waystar Holding CorporationCommon and Preferred Stock 54,639 shares2,005,251 
    TE Connectivity plcCommon and Preferred Stock 13,758 shares1,966,981 
    Sensata Technologies BV HoldingCommon and Preferred Stock 71,319 shares1,954,141 
    Generac Holdings Inc.Common and Preferred Stock 12,230 shares1,896,262 
    Uber Technologies, Inc.Common and Preferred Stock 31,333 shares1,890,007 
    Viper Energy Inc.Common and Preferred Stock 38,261 shares1,877,467 
    The Cooper Companies, Inc.Common and Preferred Stock 20,410 shares1,876,291 
    UGI CorporationCommon and Preferred Stock 65,112 shares1,838,112 
    Dynatrace Inc.Common and Preferred Stock 33,790 shares1,836,487 
    NOV Inc.Common and Preferred Stock 124,784 shares1,821,846 
    Henry Schein Inc.Common and Preferred Stock 26,178 shares1,811,518 
    13



    Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)
    Identity of IssueDescription of InvestmentCurrent Value
    Coherent CorporationCommon and Preferred Stock 18,810 shares1,781,871 
    Heico Corporation Class ACommon and Preferred Stock 9,534 shares1,774,087 
    MACOM Technology Solutions Holdings Inc.Common and Preferred Stock 13,202 shares1,715,072 
    First American Financial CorporationCommon and Preferred Stock 27,415 shares1,711,793 
    Chewy Inc. Class ACommon and Preferred Stock 50,395 shares1,687,729 
    Roblox Corporation Class ACommon and Preferred Stock 28,957 shares1,675,452 
    Veracyte Inc.Common and Preferred Stock 42,230 shares1,672,308 
    GlobalFoundries Inc.Common and Preferred Stock 38,926 shares1,670,315 
    Remitly Global Inc.Common and Preferred Stock 73,960 shares1,669,277 
    Huron Consulting Group Inc.Common and Preferred Stock 12,879 shares1,600,345 
    Dolby Laboratories Inc.Common and Preferred Stock 20,268 shares1,582,931 
    AerCap Holdings N.V.Common and Preferred Stock 16,495 shares1,578,572 
    Cabot CorporationCommon and Preferred Stock 17,076 shares1,559,210 
    Axon Enterprise, Inc.Common and Preferred Stock 2,606 shares1,548,798 
    Blackbaud, Inc.Common and Preferred Stock 20,784 shares1,536,353 
    UBS Group AGCommon and Preferred Stock 50,412 shares1,528,492 
    Woodward Inc.Common and Preferred Stock 8,908 shares1,482,469 
    Snowflake Inc. Class ACommon and Preferred Stock 9,531 shares1,471,682 
    Tandem Diabetes Care Inc.Common and Preferred Stock 40,805 shares1,469,796 
    Prosperity Bancshares Inc.Common and Preferred Stock 19,211 shares1,447,549 
    Ultragenyx Pharmaceutical Inc.Common and Preferred Stock 33,724 shares1,418,769 
    ACV Auctions Inc. Class ACommon and Preferred Stock 64,909 shares1,402,034 
    Dycom Industries Inc.Common and Preferred Stock 7,774 shares1,353,142 
    Curtiss Wright CorporationCommon and Preferred Stock 3,800 shares1,348,506 
    Belden Inc.Common and Preferred Stock 11,970 shares1,347,942 
    QuidelOrtho CorporationCommon and Preferred Stock 30,248 shares1,347,548 
    National Retail Properties Inc.Common and Preferred Stock 32,862 shares1,342,413 
    nCino, Inc.Common and Preferred Stock 39,576 shares1,328,962 
    Copart Inc.Common and Preferred Stock 23,149 shares1,328,521 
    ACI Worldwide Inc.Common and Preferred Stock 25,372 shares1,317,061 
    Mid-American Apartment Communities Inc.Common and Preferred Stock 8,492 shares1,312,608 
    Teleflex Inc.Common and Preferred Stock 7,364 shares1,310,645 
    Itron Inc.Common and Preferred Stock 11,995 shares1,302,417 
    Toro CompanyCommon and Preferred Stock 16,152 shares1,293,775 
    FMC CorporationCommon and Preferred Stock 25,597 shares1,244,270 
    Summit Materials Inc.Common and Preferred Stock 24,477 shares1,238,536 
    Advanced Energy Industries Inc.Common and Preferred Stock 10,458 shares1,209,259 
    Kirby CorporationCommon and Preferred Stock 11,215 shares1,186,547 
    Alamos Gold Inc. Class ACommon and Preferred Stock 62,978 shares1,161,314 
    Permian Resources CorporationCommon and Preferred Stock 80,643 shares1,159,646 
    WEX Inc.Common and Preferred Stock 6,610 shares1,158,865 
    Madrigal Pharmaceuticals, Inc.Common and Preferred Stock 3,721 shares1,148,189 
    Chart Industrials Inc.Common and Preferred Stock 5,976 shares1,140,460 
    BankUnited Inc.Common and Preferred Stock 29,724 shares1,134,565 
    FTI Consulting Inc.Common and Preferred Stock 5,914 shares1,130,343 
    Graco Inc.Common and Preferred Stock 13,253 shares1,117,095 
    Carlisle Companies Inc.Common and Preferred Stock 3,024 shares1,115,372 
    Middleby CorporationCommon and Preferred Stock 8,199 shares1,110,555 
    Azekpany Inc.Common and Preferred Stock 23,310 shares1,106,526 
    TKO Group Holdings Inc.Common and Preferred Stock 7,673 shares1,090,410 
    John Bean Technologies CorporationCommon and Preferred Stock 8,454 shares1,074,503 
    Iridium Communications Inc.Common and Preferred Stock 36,855 shares1,069,532 
    14



    Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)
    Identity of IssueDescription of InvestmentCurrent Value
    IAC Inc.Common and Preferred Stock 24,687 shares1,064,997 
    Rentokil Initial plcCommon and Preferred Stock 41,832 shares1,059,186 
    Hexcel CorporationCommon and Preferred Stock 16,638 shares1,043,203 
    Chemed CorporationCommon and Preferred Stock 1,945 shares1,030,461 
    National Bank Holdings Corporation Class ACommon and Preferred Stock 23,413 shares1,008,164 
    Encompass Health CorporationCommon and Preferred Stock 10,853 shares1,002,275 
    Oceaneering International Inc.Common and Preferred Stock 38,171 shares995,500 
    Certara Inc.Common and Preferred Stock 92,654 shares986,765 
    Cimpress plcCommon and Preferred Stock 13,690 shares981,847 
    JP Morgan Chase & CompanyCommon and Preferred Stock 4,083 shares978,736 
    AptarGroup Inc.Common and Preferred Stock 6,221 shares977,319 
    Supernus Pharmaceuticals Inc.Common and Preferred Stock 26,928 shares973,716 
    Ciena CorporationCommon and Preferred Stock 11,465 shares972,347 
    Range Resources CorporationCommon and Preferred Stock 26,841 shares965,739 
    Globus Medical, Inc. Class ACommon and Preferred Stock 11,648 shares963,406 
    Keysight Technologies Inc.Common and Preferred Stock 5,943 shares954,624 
    Pool CorporationCommon and Preferred Stock 2,772 shares945,086 
    ASGN Inc.Common and Preferred Stock 11,142 shares928,574 
    Barnes Group Inc.Common and Preferred Stock 19,453 shares919,349 
    Prestige Consumer Healthcare Inc.Common and Preferred Stock 11,711 shares914,512 
    Sotera Health CompanyCommon and Preferred Stock 65,963 shares902,374 
    Knowles CorporationCommon and Preferred Stock 45,024 shares897,328 
    Hannon Armstrong Sustainable Infrastructure Capital Inc.Common and Preferred Stock 33,322 shares894,029 
    On Semiconductor CorporationCommon and Preferred Stock 14,094 shares888,627 
    Box Inc. Class ACommon and Preferred Stock 27,909 shares881,924 
    KBR, Inc.Common and Preferred Stock 15,222 shares881,810 
    Federal Signal CorporationCommon and Preferred Stock 9,140 shares844,445 
    Omnicell Inc.Common and Preferred Stock 18,940 shares843,209 
    Tenable Holdings Inc.Common and Preferred Stock 21,184 shares834,226 
    WisdomTree Investments Inc.Common and Preferred Stock 79,410 shares833,805 
    Markel Corporation Holding CompanyCommon and Preferred Stock 474 shares818,233 
    Wolverine World Wide Inc.Common and Preferred Stock 36,775 shares816,405 
    Albany International Corporation Class ACommon and Preferred Stock 9,977 shares797,861 
    Applied Industrial Technologies Inc.Common and Preferred Stock 3,263 shares781,391 
    Sprout Social, Inc. Class ACommon and Preferred Stock 25,047 shares769,193 
    Haemonetics CorporationCommon and Preferred Stock 9,762 shares762,217 
    GFL Environmental Inc.Common and Preferred Stock 16,522 shares735,890 
    KB HomeCommon and Preferred Stock 10,960 shares720,291 
    Sally Beauty Holdings Inc.Common and Preferred Stock 67,967 shares710,255 
    Teledyne Technologies Inc.Common and Preferred Stock 1,508 shares699,908 
    Acadia Healthcare Company Inc.Common and Preferred Stock 16,815 shares666,715 
    SpringWorks Therapeutics Inc.Common and Preferred Stock 18,379 shares664,033 
    Core & Main, Inc. Class ACommon and Preferred Stock 13,018 shares662,746 
    Sportradar GroupCommon and Preferred Stock 37,259 shares646,071 
    ZipRecruiter Inc. Class ACommon and Preferred Stock 87,084 shares630,488 
    Consensus Cloud Solutions Inc.Common and Preferred Stock 26,157 shares624,106 
    Jacobs Solutions Inc.Common and Preferred Stock 4,667 shares623,605 
    SLR Investment CorporationCommon and Preferred Stock 36,915 shares596,546 
    J & J Snack Foods CorporationCommon and Preferred Stock 3,824 shares593,217 
    Knight-Swift Transportation Holdings Inc. Class ACommon and Preferred Stock 11,167 shares592,298 
    Heartland Express Inc.Common and Preferred Stock 52,207 shares585,763 
    15



    Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)
    Identity of IssueDescription of InvestmentCurrent Value
    Axogen Inc.Common and Preferred Stock 35,434 shares583,952 
    Carter Inc.Common and Preferred Stock 10,405 shares563,847 
    Agios Pharmaceuticals Inc.Common and Preferred Stock 17,090 shares561,577 
    CONMED CorporationCommon and Preferred Stock 7,934 shares543,003 
    Matthews International Corporation Class ACommon and Preferred Stock 19,608 shares542,749 
    United Community Bank Blairsville GeorgiaCommon and Preferred Stock 16,791 shares542,517 
    Tronox Holdings PLCCommon and Preferred Stock 52,326 shares526,923 
    Nasdaq Inc.Common and Preferred Stock 6,807 shares526,249 
    N-Able Technologies International Inc.Common and Preferred Stock 55,065 shares514,307 
    Trinet Group Inc.Common and Preferred Stock 5,655 shares513,304 
    Skechers USA Inc. Class ACommon and Preferred Stock 7,556 shares508,065 
    Banner CorporationCommon and Preferred Stock 7,545 shares503,780 
    BRP Group Inc. Class ACommon and Preferred Stock 12,962 shares502,407 
    WillScot Mobile Mini Holdings CorporationCommon and Preferred Stock 15,010 shares502,085 
    Arvinas Inc.Common and Preferred Stock 26,190 shares502,062 
    Eagle Materials Inc.Common and Preferred Stock 2,032 shares501,416 
    Legend Biotech CorporationCommon and Preferred Stock 15,404 shares501,246 
    STAG Industrial Inc.Common and Preferred Stock 14,323 shares484,404 
    Crescent Energy Company Class ACommon and Preferred Stock 33,122 shares483,912 
    Elastic N.V.Common and Preferred Stock 4,872 shares482,718 
    Axalta Coating Systems LimitedCommon and Preferred Stock 13,877 shares474,871 
    Cohen & Steers Inc.Common and Preferred Stock 5,070 shares468,164 
    Matson Inc.Common and Preferred Stock 3,438 shares463,580 
    TreeHouse Foods Inc.Common and Preferred Stock 13,185 shares463,189 
    Wabtec CorporationCommon and Preferred Stock 2,384 shares451,983 
    Align Technology Inc.Common and Preferred Stock 2,115 shares440,999 
    JBG SMITH PropertiesCommon and Preferred Stock 28,050 shares431,129 
    Exact Sciences CorporationCommon and Preferred Stock 7,631 shares428,786 
    Fox Factory Holding CorporationCommon and Preferred Stock 14,156 shares428,502 
    GXO Logistics Inc.Common and Preferred Stock 9,834 shares427,779 
    Pacific Premier Bancorp Inc.Common and Preferred Stock 17,052 shares424,936 
    Littelfuse Inc.Common and Preferred Stock 1,788 shares421,342 
    Northern Oil & Gas Inc.Common and Preferred Stock 11,292 shares419,611 
    Silgan Holdings Inc.Common and Preferred Stock 8,042 shares418,586 
    Flowserve CorporationCommon and Preferred Stock 7,035 shares404,653 
    First Interstate BancSystemCommon and Preferred Stock 12,177 shares395,387 
    8X8 Inc.Common and Preferred Stock 146,281 shares390,570 
    NorthWestern CorpCommon and Preferred Stock 6,742 shares360,427 
    ALLETE Inc.Common and Preferred Stock 5,552 shares359,770 
    Monro Inc.Common and Preferred Stock 14,442 shares358,162 
    WSFS Financial CorporationCommon and Preferred Stock 6,655 shares353,580 
    Mercury Systems Inc.Common and Preferred Stock 8,249 shares346,458 
    Healthpeak OP, LLCCommon and Preferred Stock 16,916 shares342,887 
    Texas Capital Bancshares Inc.Common and Preferred Stock 4,344 shares339,701 
    Americold Realty Trust, Inc.Common and Preferred Stock 15,870 shares339,618 
    Amentum Holdings, Inc.Common and Preferred Stock 15,523 shares326,449 
    Boston Properties Inc.Common and Preferred Stock 4,078 shares303,240 
    Patterson-UTI Energy Inc.Common and Preferred Stock 36,005 shares297,401 
    NCR CorporationCommon and Preferred Stock 21,092 shares291,913 
    Dyne Therapeutics, Inc.Common and Preferred Stock 12,003 shares282,791 
    1-800-FLOWERS.COM Inc. Class ACommon and Preferred Stock 34,533 shares282,135 
    16



    Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)
    Identity of IssueDescription of InvestmentCurrent Value
    Sonos Inc.Common and Preferred Stock 17,904 shares269,276 
    IPG Photonics CorporationCommon and Preferred Stock 3,635 shares264,337 
    Rogers CorporationCommon and Preferred Stock 2,553 shares259,410 
    StandardAero, Inc.Common and Preferred Stock 10,216 shares252,948 
    Nevro CorporationCommon and Preferred Stock 67,978 shares252,878 
    Berkshire Hills Bancorp Inc.Common and Preferred Stock 8,643 shares245,720 
    Transmedics Group Inc.Common and Preferred Stock 3,605 shares224,772 
    Mednax Inc.Common and Preferred Stock 16,137 shares211,717 
    Nuvalent, Inc. Class ACommon and Preferred Stock 2,674 shares209,321 
    Columbus McKinnon CorporationCommon and Preferred Stock 4,724 shares175,922 
    Insight Enterprises, Inc.Common and Preferred Stock 1,156 shares175,828 
    Designer Brands Inc. Class ACommon and Preferred Stock 32,021 shares170,992 
    Herbalife Nutrition LimitedCommon and Preferred Stock 24,148 shares161,550 
    eHealth Inc.Common and Preferred Stock 12,746 shares119,812 
    Nu Skin Enterprises Inc. Class ACommon and Preferred Stock 12,954 shares89,253 
    Safehold Inc.Common and Preferred Stock 4,652 shares85,969 
    Total U.S. Equity Active Asset Class679,117,526 
    U.S. Equity Index Asset Class:
    NT Collective Russell 3000 Index Fund / Non Lending*Collective Trust Fund 22,328,542 units2,073,570,958 
    Gaming & Leisure Properties Inc.Common and Preferred Stock 155 shares7,465 
    CTO Realty Growth Inc.Common and Preferred Stock 83 shares1,636 
    NT Collective Short Term Investment Fund*Collective Trust Fund 328 units328 
    Total U.S. Equity Index Asset Class2,073,580,387 
    International Equity Active Asset Class:
    Mawer International Equity Collective Investment Trust Class B*Collective Trust Fund 14,497,735 units256,920,164 
    Polaris Capital Management Collective Investment Trust International Value Collective Fund*Collective Trust Fund 20,282,037 units246,142,798 
    Reliance Trust Institutional Retirement Trust GQG Partners International Equity Fund Series 11 Class C*Collective Trust Fund 11,706,978 units186,492,162 
    Dodge & Cox International Stock FundMutual Fund 2,982,883 shares148,845,846 
    Wilmington Trust Collective Investment Trust / Jennison International Equity Opportunities CIT Class J*Collective Trust Fund 14,454,657 units144,662,208 
    NT Collective MSCI All Country World Index (ACWI) ex/US Index Fund / Non Lending*Collective Trust Fund 566,056 units127,783,078 
    NT Collective Short Term Investment Fund*Collective Trust Fund 38,030 units38,030 
    Total International Equity Active Asset Class1,110,884,286 
    International Equity Index Asset Class:
    NT Collective All Country World Index (ACWI) Ex/US Fund / Non Lending*Collective Trust Fund 1,492,119 units307,495,939 
    Total International Equity Index Asset Class307,495,939 
    Participant Self-Directed AccountsVarious Investments999,716,674 
    999,716,674 
    Notes Receivable from Participants*Interest Rate 4.25% - 9.50%35,185,439 
    35,185,439 
    17



    Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)
    Identity of IssueDescription of InvestmentCurrent Value
    Other:
    BIF Money Fund*Cash and Cash Equivalents2,689,633 
    ML Vanguard Federal Money Market Forfeiture / Settlement*Cash and Cash Equivalents715,843 
    NT Collective Short Term Investment Fund*Collective Trust Fund 358,375 units358,375 
    Interest-Bearing CashCash and Cash Equivalents61,082 
    Exide TechnologiesCommon and Preferred Stock 35,683 shares24,978 
    Total Other3,849,911 
    Grand Total$7,718,743,607 
    * Indicates party-in-interest

    18


    AMGEN RETIREMENT AND SAVINGS PLAN
    INDEX TO EXHIBIT
     
    Consent of Independent Registered Public Accounting Firm
      Exhibit 23.1
    19


    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.
      
     Amgen Retirement and Savings Plan
     (Name of Plan)
    Date:June 12, 2025 By: /s/ PETER H. GRIFFITH
       
    Peter H. Griffith
       
    Executive Vice President and
    Chief Financial Officer
    Amgen Inc.
    20
    Get the next $AMGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMGN

    DatePrice TargetRatingAnalyst
    5/20/2025$288.00Neutral
    Guggenheim
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    12/10/2024$256.00Underperform
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/14/2024$335.00Neutral
    Citigroup
    10/17/2024$380.00Outperform
    Bernstein
    10/14/2024$320.00 → $333.00Buy → Hold
    Truist
    9/27/2024$405.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Amgen Inc converted options into 33,603,948 shares and bought $29,999,985 worth of shares (1,764,705 units at $17.00)

      4 - AMGEN INC (0000318154) (Reporting)

      9/19/23 7:52:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

      The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: https://www.multivu.com/amgen/9340551-en-amgen-barry-sanders-highlight-dangers-bad-cholesterol-new-documentary The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he expe

      6/13/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

      THOUSAND OAKS, Calif., June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found

      6/5/25 4:01:00 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BetterInvesting™ Magazine Update on The Walt Disney Co. (NYSE: DIS)

      TROY, Mich., June 5, 2025 /PRNewswire/ -- Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August. The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for inv

      6/5/25 1:58:00 PM ET
      $AMGN
      $DIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Guggenheim resumed coverage on Amgen with a new price target

      Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00

      5/20/25 8:11:08 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Amgen with a new price target

      Cantor Fitzgerald resumed coverage of Amgen with a rating of Neutral and set a new price target of $305.00

      4/22/25 7:29:10 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities resumed coverage on Amgen with a new price target

      BofA Securities resumed coverage of Amgen with a rating of Underperform and set a new price target of $256.00

      12/10/24 8:12:28 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

      Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver

      5/18/23 8:00:00 AM ET
      $ALLO
      $AMGN
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS

      THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately.  Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee.  Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent. Dr. Drake is president of the University of California, a system of 10 campuses, five medical centers and three nationally affiliated labs that serves more than 280,000 students and employs 230,000 faculty and staff. "Michael is an accomplished physician an

      8/3/22 4:05:00 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Financials

    Live finance-specific insights

    See more

    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

      The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: https://www.multivu.com/amgen/9340551-en-amgen-barry-sanders-highlight-dangers-bad-cholesterol-new-documentary The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he expe

      6/13/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS

      Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy  Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3

      6/2/25 8:04:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered

      5/1/25 4:01:00 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      2/13/24 4:58:51 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      1/30/24 11:35:57 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Amgen Inc.

      SC 13D - AMGEN INC (0000318154) (Filed by)

      9/27/23 7:30:51 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      11/21/24 12:43:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for PAVBLU issued to AMGEN INC

      Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

      8/26/24 5:53:38 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      8/21/24 12:12:47 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Business Development Khosla Rachna sold $434,520 worth of shares (1,500 units at $289.68), decreasing direct ownership by 16% to 8,162 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      6/6/25 7:49:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miles Amy E was granted 809 shares, increasing direct ownership by 20% to 4,842 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:07:13 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kullman Ellen Jamison was granted 809 shares, increasing direct ownership by 6% to 13,467 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:06:19 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    SEC Filings

    See more
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:46:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:42:09 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Amgen Inc.

      10-Q - AMGEN INC (0000318154) (Filer)

      5/1/25 6:54:46 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care